Hypermethylated DAPK in serum DNA of women with uterine leiomyoma is a biomarker not restricted to cancer

Gynecologic Oncology

Volumn 121, Issue 1, 2011, Pages 224-229

  Häfner, Norman ^a   Diebolder, Herbert ^a   Jansen, Lars ^a   Hoppe, Ines ^a   Dürst, Matthias ^a   Runnebaum, Ingo B ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

DAPK; Diagnostic serum marker; Hypermethylation; Leiomyoma; Ovarian cancer

Indexed keywords

BIOLOGICAL MARKER; DEATH ASSOCIATED PROTEIN KINASE; GENOMIC DNA; TUMOR MARKER;

ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DNA METHYLATION; DNA SEQUENCE; EARLY DIAGNOSIS; FEMALE; HUMAN; HUMAN TISSUE; POLYMERASE CHAIN REACTION; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; UTERUS CANCER; UTERUS MYOMA;

APOPTOSIS REGULATORY PROTEINS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASES; DNA METHYLATION; DNA, NEOPLASM; FEMALE; HELA CELLS; HUMANS; LEIOMYOMA; TUMOR MARKERS, BIOLOGICAL; UTERINE NEOPLASMS;

EID: 79952817426     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.11.018     Document Type: Article

References (40)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Berrino F. The EUROCARE study: strengths, limitations and perspectives of population-based, comparative survival studies. Ann Oncol 2003;14(Suppl 5):v9-v13. (Pubitemid 46417460)
3. Cannistra SA. Cancer of the ovary. N Engl J Med 2004;351:2519-29.
4. Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 2004;3:355-66. (Pubitemid 38702089)
5. Anderson GL, McIntosh M, Wu L, Barnett M, Goodman G, Thorpe JD, et al. Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J Natl Cancer Inst 2010;102:26-38.
6. Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, et al. Sensitivity and specificity ofmultimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 2009;10:327-40.
7. Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, et al. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 2008;14:1065-72. (Pubitemid 351302552)
8. Leiserowitz GS, Lebrilla C, Miyamoto S, An HJ, Duong H, Kirmiz C, et al. Glycomics analysis of serum: a potential new biomarker for ovarian cancer? Int J Gynecol Cancer 2008;18:470-5. (Pubitemid 351668296)
9. Stroun M, Anker P, Maurice P, Lyautey J, Lederrey C, Beljanski M. Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology 1989;46:318-22. (Pubitemid 19216753)
10. Hickey KP, Boyle KP, Jepps HM, Andrew AC, Buxton EJ, Burns PA. Molecular detection of tumour DNA in serum and peritoneal fluid from ovarian cancer patients. Br J Cancer 1999;80:1803-8. (Pubitemid 29389636)
11. Swisher EM, Wollan M, Mahtani SM, Willner JB, Garcia R, Goff BA, et al. Tumor-specific p53 sequences in blood and peritoneal fluid of women with epithelial ovarian cancer. Am J Obstet Gynecol 2005;193:662-7. (Pubitemid 41261459)
12. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70. (Pubitemid 30046295)
13. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-28. (Pubitemid 34587077)
14. Sidransky D. Emerging molecular markers of cancer. Nat Rev Cancer 2002;2:210-9. (Pubitemid 37328790)
15. Bird AP. CpG-rich islands and the function of DNA methylation. Nature 1986;321: 209-13. (Pubitemid 16016411)
16. Eden A, Gaudet F, Waghmare A, Jaenisch R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 2003;300:455. (Pubitemid 36444319)
17. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-54. (Pubitemid 37448928)
18. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007;128:683-92. (Pubitemid 46273572)
19. Widschwendter M, Fiegl H, Egle D, Mueller-Holzner E, Spizzo G, Marth C, et al. Epigenetic stem cell signature in cancer. Nat Genet 2007;39:157-8. (Pubitemid 46184343)
20. Schlesinger Y, Straussman R, Keshet I, Farkash S, Hecht M, Zimmerman J, et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 2007;39:232-6. (Pubitemid 46184355)
21. Barton CA, Hacker NF, Clark SJ, O'Brien PM. DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment. Gynecol Oncol 2008;109:129-39.
22. Ibanez de Caceres I, Battagli C, Esteller M, Herman JG, Dulaimi E, Edelson MI, et al. Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res 2004;64:6476-81. (Pubitemid 39297903)
23. Melnikov A, Scholtens D, Godwin A, Levenson V. Differential methylation profile of ovarian cancer in tissues and plasma. J Mol Diagn 2009;11:60-5.
24. Diamandis EP. Cancer biomarkers: can we turn recent failures into success? J Natl Cancer Inst 2010;102:1462-7.
25. Buttram Jr VC. Uterine leiomyomata-aetiology, symptomatology and management. Prog Clin Biol Res 1986;225:275-96.
26. Okolo S. Incidence, aetiology and epidemiology of uterine fibroids. Best Pract Res Clin Obstet Gynaecol 2008;22:571-88. (Pubitemid 351804127)
27. Wu TL, Zhang D, Chia JH, Tsao KH, Sun CF, Wu JT. Cell-free DNA: measurement in various carcinomas and establishment of normal reference range. Clin Chim Acta 2002;321:77-87. (Pubitemid 34597056)
28. Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci USA 2005;102:16368-73. (Pubitemid 41688920)
29. Katzenellenbogen RA, Baylin SB, Herman JG. Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies. Blood 1999;93:4347-53. (Pubitemid 29279278)
30. Wisman GB, Nijhuis ER, Hoque MO, Reesink-Peters N, Koning AJ, Volders HH, et al. Assessment of gene promoter hypermethylation for detection of cervical neoplasia. Int J Cancer 2006;119:1908-14. (Pubitemid 44356850)
31. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001;61:3225-9. (Pubitemid 32695003)
32. Narayan G, Arias-Pulido H, Koul S, Vargas H, Zhang FF, Villella J, et al. Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome. Mol Cancer 2003;2:24.
33. Gonzalez-Gomez P, Bello MJ, Arjona D, Lomas J, Alonso ME, De Campos JM, et al. Promoter hypermethylation of multiple genes in astrocytic gliomas. Int J Oncol 2003;22:601-8.
34. Collins Y, Dicioccio R, Keitz B, Lele S, Odunsi K. Methylation of death-associated protein kinase in ovarian carcinomas. Int J Gynecol Cancer 2006;16(Suppl 1):195-9.
35. Teodoridis JM, Hall J, Marsh S, Kannall HD, Smyth C, Curto J, et al. CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res 2005;65:8961-7. (Pubitemid 41377387)
36. Terasawa K, Sagae S, Toyota M, Tsukada K, Ogi K, Satoh A, et al. Epigenetic inactivation of TMS1/ASC in ovarian cancer. Clin Cancer Res 2004;10:2000-6. (Pubitemid 38375559)
37. Khalique L, Ayhan A, Weale ME, Jacobs IJ, Ramus SJ, Gayther SA. Genetic intra-tumour heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of tumours. J Pathol 2007;211:286-95. (Pubitemid 46172704)
38. Davidson B. Anatomic site-related expression of cancer-associated molecules in ovarian carcinoma. Curr Cancer Drug Targets 2007;7:109-20. (Pubitemid 46345512)
39. Reddy AN, Jiang WW, Kim M, Benoit N, Taylor R, Clinger J, et al. Death-associated protein kinase promoter hypermethylation in normal human lymphocytes. Cancer Res 2003;63:7694-8. (Pubitemid 37466698)
40. Shen L, Kondo Y, Guo Y, Zhang J, Zhang L, Ahmed S, et al. Genome-wide profiling of DNA methylation reveals a class of normally methylated CpG island promoters. PLoS Genet 2007;3:2023-36.